GI Associates joins forces with the Sarah Cannon Research Institute (SCRI) in an effort to grow the clinical research program in our practice. Working with SCRI enables us to provide greater access to clinical trials for our patients. Together, GI Associates and SCRI work to provide the latest treatment options with consistent, quality care and novel therapies to the communities of southwest Tennessee.
The benefits of this relationship are far-reaching for GI Associates patients and their families. Some of the benefits include:
· Expanded treatment options -- improved local access to clinical trials and leading-edge treatments that can be administered close to home;
· Consistent care -- an increased ability to retain continuity of care with physicians they know and trust; and
· Innovative medicine -- the ability to participate in research trials with promising drug combination therapies.
By partnering with SCRI, GI Associates has access to a research institution that conducts a number of clinical trials and one of the largest, community-based disease research support programs offering management, regulatory and other clinical research support services to physician researchers in over ten therapeutic areas and research sponsors across the country. Through a powerful national network of hundreds of physicians, SCRI supports advancements in clinical research and provides greater access to clinical trials in a community-based setting.
GI Associates is determined to make a difference through its clinical research support program with access to a variety of clinical trials in several therapeutic areas, in active enrollment and follow-up. Through these trials, patients are able to receive innovative new treatments in the communities we serve.
Click Here to learn more information about SCRI and to view a list of active clinical trials. If you are interested in becoming a study participant, click here